Search

Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD, a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment, which is effective immediately, Dr. Cahlon will help oversee the network’s outpatient clinical programs, which span seven locations across New York and New Jersey.

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).

MSK President and CEO, Craig B. Thompson, MD, has been named a founding member of the New York Jobs CEO Council. Dr. Thompson joins CEOs from 27 of the largest employers in New York in the new CEO-led, action-oriented coalition.

Scientists are dusting off their biochemistry textbooks in the hunt for clues to cancer.

In the past 30 years, major strides have been made in translational medicine — the bridge that shepherds research findings from the lab to clinical practice. Researchers, physicians, and other specialists at Memorial Sloan Kettering Cancer Center (MSK) have played a major role in these successes, as they work together with the common goal of using their discoveries to create new treatments for people with cancer.

The list honors health care leaders who envision a better future for all New Yorkers.

Sometimes a BRCA mutation is just along for the ride, rather than driving a tumor’s development.

A team of doctors and researchers at MSK have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Learn how one 19-year-old patient sparked a detective story.